# A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval

> **NCT03577275** · PHASE1 · COMPLETED · sponsor: **NorthSea Therapeutics B.V.** · enrollment: 32 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** NST-4016 600mg
- **DRUG:** Placebo oral capsule
- **DRUG:** Moxifloxacin 400mg
- **DRUG:** NST-4016 2000mg

## Key facts

- **NCT ID:** NCT03577275
- **Lead sponsor:** NorthSea Therapeutics B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-15
- **Primary completion:** 2018-09-15
- **Final completion:** 2018-09-24
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03577275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03577275, "A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03577275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*